Long-Term Safety of Ixekizumab Treatment in Adult Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: A Post-Hoc Analysis of End-Of-Study Program Data Relating to Major Adverse Cardiovascular Events

This study analyzed the long-term safety of Ixekizumab (IXE) in adult patients with psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (AxSpA) over 5 and 3 years, respectively, focusing on major adverse cardiovascular events (MACE). Across 25 clinical trials, the incidence rates of MACE were low: 0.5 per 100 patient-years for both PsO and PsA, and 0.3 for axSpA. In the PsO cohort, 103 MACE cases were reported, with 19.4% fatality, while PsA had 12 cases with 16.7% fatality, and all 6 cases in axSpA recovered. The most common MACE types were non-fatal myocardial infarction, nonfatal stroke, and vascular death. Overall, the incidence of MACE remained low and stable throughout the treatment periods.